Curcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouse

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Micucci, Matteo ^a   Aldini, Rita ^a   Cevenini, Monica ^a   Colliva, Carolina ^a   Spinozzi, Silvia ^a   Roda, Giulia ^a   Montagnani, Marco ^a   Camborata, Cecilia ^a   Camarda, Luca ^a   Chiarini, Alberto ^a   Mazzella, Giuseppe ^a   Budriesi, Roberta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; HISTAMINE RECEPTOR; LIPID; PLANT EXTRACT; SEROTONIN RECEPTOR; TURMERIC EXTRACT;

ANIMAL; AORTA; BAGG ALBINO MOUSE; BLADDER; BLOOD; CURCUMA; DRUG EFFECTS; DRUG SCREENING; GALLBLADDER; GASTROINTESTINAL MOTILITY; HEART; INTESTINE; LIVER; LIVER FUNCTION TEST; MALE; METABOLISM; MOUSE; MUSCLE CONTRACTION; PHYSIOLOGY; SMOOTH MUSCLE; TRACHEA;

ANIMALS; AORTA; BILE ACIDS AND SALTS; CURCUMA; DRUG EVALUATION, PRECLINICAL; GALLBLADDER; GASTROINTESTINAL MOTILITY; HEART; INTESTINES; LIPIDS; LIVER; LIVER FUNCTION TESTS; MALE; MICE; MICE, INBRED BALB C; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PARASYMPATHOLYTICS; PLANT EXTRACTS; RECEPTORS, CHOLINERGIC; RECEPTORS, HISTAMINE; RECEPTORS, SEROTONIN; TRACHEA; URINARY BLADDER;

EID: 84894032613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080925     Document Type: Article

References (64)

1. Fan X, Zhang C, Liu DB, Yan J, Liang HP (2013) The Clinical Applications of Curcumin: Current State and the Future. Curr Pharm Des 19(11): 2011-2031. doi:10.2174/138161213805289255. PubMed: 23116310.
2. Noorafshan A, Ashkani-Esfahani S (2013) A Review of therapeutic effects of Curcumin. Curr Pharm Des 19(11): 2032-2046. doi:10.2174/138161213805289273. PubMed: 23116311.
3. Huang TS, Lee SC, Lin JK (1991) Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci U S A 88: 5292-5296. doi:10.1073/pnas.88.12.5292. PubMed: 1905019.
4. Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J et al. (2009) Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. Bioorg Med Chem 17(23): 8027-8031. doi:10.1016/j.bmc.2009. 10.006. PubMed: 19857970.
5. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y et al. (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 12: 1502-1506. PubMed: 17101300. (Pubitemid 44880023)
6. Negi PS, Jayaprakasha GK, Mohan Rao Jagan L, Sakariah KK (1999) Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 47: 4297-4300. (Pubitemid 29506239)
7. Xu YX, Pindolia KR, Janakiraman N (1997) Curcumin, a compound with anti inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Exp Hematol 25: 413-422. PubMed: 9168063. (Pubitemid 27226860)
8. Xia Q, Wang X, Xu DJ, Chen XH, Chen FH (2012) Inhibition of platelet aggregation by curdione from Curcuma wenyujin essential Oil. Thromb Res 130(3): 409-414. doi:10.1016/j.thromres.2012.04.005. PubMed: 22560337.
9. Zhao JF, Ching LC, Huang YC, Chen CY, Chiang AN (2012) Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis. Mol Nutr Food Res 56(5): 691-701. doi:10.1002/mnfr.201100735. PubMed: 22648616.
10. Orellana-Paucar AM, Serruys AS, Afrikanova T, Maes J, De Borggraeve W (2012) Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models. Epilepsy Behav 24(1): 14-22. doi:10.1016/j.yebeh. 2012.02.020. PubMed: 22483646.
11. Khaw AK, Hande MP, Kalthur G, Hande MP (2013) Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells. J Cell Biochem 14(16): 1257-1270. PubMed: 23192708.
12. Kurapati KR, Samikkannu T, Kadiyala DB, Zainulabedin SM, Gandhi N et al. (2012) Combinatorial cytotoxic effects of Curcuma longa and Zingiber officinale on the PC-3M prostate cancer cell line. J Basic Clin Physiol Pharmacol 23(4): 139-146. PubMed: 23072849.
13. Singh AK, Sidhu GS, Deepa T, Maheshwari RK (1996) Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Lett 107: 109-115. doi:10.1016/0304-3835(96)04357-1. PubMed: 8913274. (Pubitemid 26370865)
14. Sun XD, Liu XE, Huang DS (2012) Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Mol Med Report 6(6):1267-70
15. Reuland DJ, Khademi S, Castle CJ, Irwin DC, McCord JM (2013) Upregulation of phase II enzymes through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress. Free Radic Biol Med 56: 102-111. doi:10.1016/j.freeradbiomed.2012.11.016. PubMed: 23201694.
16. Qin XY, Lv JH, Cui J, Fang X, Zhang Y (2012) Curcumin protects against staurosporine toxicity in rat neurons. Neurosci Bull 28(5): 606-610. doi:10.1007/s12264-012-1275-x. PubMed: 23054638.
17. Ahmed T, Gilani AH (2008) Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav 91: 554-555. PubMed: 18930076.
18. Hurley LL, Akinfiresoye L, Nwulia E, Kamiya A, Kulkarni AA et al. (2012) Antidepressant-like effects of curcumin in WKY rat model of depression is associated with an increase in hippocampal BDNF. Behav Brain Res 239C: 27-30. PubMed: 23142609.
19. Kim DS, Kim JY, Han Y (2012) Curcuminoids in neurodegenerative diseases. Recent Pat CNs Drugs Discov 7(3): 184-204. doi:10.2174/157488912803252032. PubMed: 22742420.
20. Su J, Sripanidkulchai K, Wyss JM, Sripanidkulchai B (2010) Curcuma comosa improbe learning and memory function on ovariectomized rats in a long-term Morris water maze test. J Ethnopharmacol 130(1): 70-75. doi:10.1016/j.jep.2010. 04.012. PubMed: 20420894.
21. Kaur CD, Saraf S (2011) Topical vesicular formulations of Curcuma longa extract on recuperating the ultraviolet radiation-damaged skin. J Cosmet Dermatol 10(4): 260-265. doi:10.1111/j.1473-2165.2011.00586.x. PubMed: 22151933.
22. Saelee C, Thongrakard V, Tencomnao T (2011) Effects of Thai medicinal herb extracts with anti-psoriatic activity on the expression on NF-κB signaling biomarkers in HaCaT keratinocytes. Molecules 16(5): 3908-3932. PubMed: 21555979.
23. Sahebkar A (2012) Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors, 39: 2012 Dec 13. doi:10.1002/biof.1062. PubMed: 23239418.
24. Madkor HR, Mansour SW, Ramadan G (2011) Modulatory effects of garlic, ginger, turmeric and their mixture on hyperglycaemia, dyslipidaemia and oxidative stress in streptozotocin-nicotinamide diabetic rats. Br J Nutr 105(8): 1210-1217. doi:10.1017/S0007114510004927. PubMed: 21144104.
25. Jitoe-Masuda A, Fujimoto A, Masuda T. (2013) Curcumin: from chemistry to chemistry-based functions. Curr Pharm Des 19(11): 2084-2092. PubMed: 23116314.
26. Ervin CM, Mangel AW (2013) Clinical Trials in Irritable Bowel Syndrome: A Review. Rev Recent Clin Trials 8(1):9-22. PubMed: 23130604.
27. Leray V, Freuchet B, Le Bloc'h J, Jeusette I, Torre C et al. (2011) Effect of citrus polyphenol- and curcumin-supplemented diet on inflammatory state in obese cats. Br J Nutr 106, Suppl 1: S198-S201. doi:10.1017/ S0007114511002492. PubMed: 22005428.
28. Gupta SC, Patchva S, Aggarwal BB (2013) Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. AAPS J 15(1): 195-218. doi:10.1208/s12248-012-9432-8. PubMed: 23143785.
29. Liju VB, Jeena K, Kuttan R (2013) Acute and subchronic toxicity as well as mutagenic evaluation of essential oil from turmeric (Curcuma longa L). Food Chem Toxicol 53: 52-61. doi:10.1016/j.fct.2012.11.027. PubMed: 23201370.
30. Chainani-Wu N (2003) Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9(1): 161-168. doi:10.1089/107555303321223035. PubMed: 12676044.
31. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS (1980) Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guinea pigs & monkeys. Indian J Exp Biol 18(1): 73-75. PubMed: 6772551. (Pubitemid 10143537)
32. Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM et al. (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6: 10-11. doi:10.1186/1472-6882-6-10. PubMed: 16545122.
33. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6): 807-818. doi:10.1021/mp700113r. PubMed: 17999464.
34. Pan MH, Huang TM, Lin JK (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27(4): 486-494. PubMed: 10101144.
35. Sharma RA, Steward WP, Gescher AJ (2007) Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 595: 453-470. doi:10.1007/978-0-387-46401-5-20. PubMed: 17569224.
36. Luo CF, Yuan M, Chen MS, Liu SM, Zhu L et al. (2011) Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm 410(1/2): 138-144. PubMed: 21392565.
37. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon BM (2011) Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74(4): 664-669. doi:10.1021/np1007262. PubMed: 21413691.
38. Tsai YM, Chien CF, Lin LC, Tsai TH (2011) Curcumin and its nanoformulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm 416(1): 331-338. doi:10.1016/j.ijpharm.2011.06.030. PubMed: 21729743.
39. Deters M, Klabunde T, Meyer H, Resch K, Kaever V (2003) Effects of curcumin on cyclosporine-induced cholestasis and hypercholesterolemia and on cyclosporine metabolism in the rat. Planta Med 69(4): 337-343. doi:10.1055/s-2003-38870. PubMed: 12709901. (Pubitemid 36578000)
40. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661. PubMed: 17942826. (Pubitemid 351348146)
41. Budriesi R, Ioan P, Micucci M, Micucci E, Limongelli V et al. (2010) Stop Fitan: antispasmodic effect of natural extract of chestnut wood in guinea pig ileum and proximal colon smooth muscle. J Med Food 13(5): 1104-1110. doi:10.1089/jmf.2009.0210. PubMed: 20626243.
42. Tallarida RJ, Murray RB (1987) Manual of Pharmacologic Calculations with Computer Programs, 2nd ed. New York: Springer-Verlag.
43. Motulsky H, Christopoulos A Fitting Models to Biological Data Using Linear and Non Linear Regression, GrafhPad, La Jolla, CA, 2003, www. Retrieved onpublished at whilst December year 1111 from graphpad.com/manual/Prism4/ RegressionBook.pdf. Accessed May 10, 2010
44. Version 3.0; GraphPad San Diego, CA, USA: Software, Inc..
45. Roda A, Gioacchini AM, Cerrè C, Baraldini M (1995) High-performance liquid chromatographic-electrospray mass spectrometric analysis of bile acids in biological fluids. J Chromatogr B Appl: Biomed 665(2): 281-94. PubMed: 7795808.
46. Itthipanichpong C, Ruangrungsi N, Kemsri W, Sawasdipanich A (2003) Antispasmodic effects of curcuminoids on isolated guinea-pig ileum and rat uterus. J Med Assoc Thai 86 Suppl 2: S2999-S2309. PubMed: 12930003.
47. Carosati E, Cruciani G, Chiarini A, Budriesi R, Ioan P et al. (2006) Calcium channel antagonists discovered by a multidisciplinary approach. J Med Chem 49(17): 5206-5216. doi:10.1021/jm0604373. PubMed: 16913709. (Pubitemid 44260216)
48. Budriesi R, Ioan P, Leoni A, Pedemonte N, Locatelli A et al. (2011) Cystic fibrosis: a new target for 4-Imidazo[2,1-b]thiazole-1,4- dihydropyridines]. J Med Chem 54(11): 3885-3894. doi:10.1021/jm200199r. PubMed: 21568323.
49. De Ponti F (2013) Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front. Pharmacologist 4: 7. doi:10.3389/fphar.2013.00007.
50. Rahimi R, Abdollahi M (2012) Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol 18: 589-600. doi:10.3748/wjg.v18.i7.589. PubMed: 22363129.
51. Balestra B, Vicini R, Cremon C, Zecchi L, Dothel G et al. (2012) Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motorneurons. Neurogastroenterol Motil 24: 1118-e570. doi:10.1111/nmo.12000. PubMed: 22937879.
52. De Ponti F (2004) Pharmacology of serotonin: what a clinician should know. Gut 53: 1520-1535. doi:10.1136/gut.2003.035568. PubMed: 15361507.
53. Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF et al. (2011) Intestinal sero-tonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 106: 1290-1298. doi:10.1038/ajg.2011.86. PubMed: 21427712.
54. Moynihan R (2002) Alosetron:a case study in regulatory capture,or a victory for patients'rights? BMJ 325: 592-595. doi:10.1136/bmj.325.7364.592. PubMed: 12228140.
55. Marzio L (2003) Factors affecting gallbladder motility: drugs. Dig Liver Dis 35 Suppl 3: S17-S19. doi:10.1016/S1590-8658(03)00088-4. PubMed: 12974504.
56. Trendle MC, Moertel CG, Kvols LK (1997) Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 79: 830-834. doi:10.1002/(SICI)1097- 0142(19970215)79:4. PubMed: 9024721. (Pubitemid 27076349)
57. Venneman NG, van Erpecum KJ (2006) Gallstone disease: Primary and secondary prevention. Best Pract Res Clin Gastroenterol 20: 1063-1073. doi:10.1016/j.bpg.2006.03.008. PubMed: 17127188. (Pubitemid 44793724)
58. Rasyid A, Lelo A (1999) The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 13(2): 245-249) doi:10.1046/j.1365-2036.1999.00464.x. PubMed: 10102956.
59. Lee JH, Oh JH, Lee YJ (2012) Biliary excretion of curcumin is mediated by multidrug resistance-associated protein 2. Biol Pharm Bull 35(5): 777-780. doi:10.1248/bpb.35.777. PubMed: 22687416.
60. Wortelboer HM, Usta M, van der Velde AE, Boersma MG, Spenkelink B et al. (2003) Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol 16: 1642-1651. doi:10.1021/tx034101x. PubMed: 14680379. (Pubitemid 38049384)
61. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L et al. (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273: 10046-10050. doi:10.1074/jbc.273.16.10046. PubMed: 9545351. (Pubitemid 28183107)
62. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118: 422-430. doi:10.1016/S0016-5085(00)83800-7. PubMed: 10648470. (Pubitemid 30067515)
63. Stieger B, Hagenbuch B, Landmann L, Höchli M, Schroeder A, Meier PJ (1994) In situ localization of the hepatocytic Na+/taurocholate cotransporting polypeptide in rat liver. Gastroenterology 107: 1781-1787. PubMed: 7958692. (Pubitemid 24357634)
64. BBON Stieger, Meier PJ (1992) ATP-dependent bile-salt transport in canalicular rat liver plasma-membrane vesicles. Biochem J 284: 67-74. PubMed: 1599411.